Qiming Medical United Dehong Capital and Qiming Ventures launched the medical investment platform to strategically lay out the global innovative medical device industry.

Guide: Venture capital institutions focus on the layout of medical devices, integration of industry resourcesOn July 16, Hangzhou Qiming Medical Devices Co., Ltd("Kiming Medical") and Dehong Capital and Qiming Ventures announced the signing of an agreement to jointly launch the new medical investment platform Jishi Capital!---- Jishi Capital aims to invest in the global innovative medical device technology of the heart and lung industry, with the help of The Industry Resources of Qiming Medical, and the capital strength of Dehong Capital and Qiming Ventures, to introduce foreign advanced technology and products, accelerate its research and development and commercialization process in China, while promoting the research and development of China's independent property rights, cultivating and integrating more industry-leading medical device enterprises, and promoting the development of innovative medical devices in ChinaLed by MsYing Ying, a well-known former Credit Suisse medical analyst, Jishi Capital has assembled a team of professionals with extensive industry investment experience and outstanding global operational capabilities"We are confident that we will develop Jishi Capital into an industry-leading investment platform for medical devices to promote the commercialization of outstanding innovative technologies and products," she saidQiming Medical is China's largest medical device company for cathetered heart valvesIn December 2019, Qiming Medical was successfully listed in Hong Kong with a current market value of over HK$31 billionIts first generation of transdermal interventional heart valve system (TAVR) product VenusA was approved by the State Drug Administration (NMPA) in April 2017 and is the first TAVR product to be approved for market in ChinaAt the same time, Qiming Medical also has a rich product pipeline covering all four heart valvesQiming Medical's long-term goal is to become a global leader in the development and commercialization of minimally invasive solutions for cardiovascular disease through research, collaboration and mergers and acquisitionsAs an industry leader, Qiming Medical has a strong research and development capability and a global network of resources to provide The Latest Technology Insights and first-line clinical experience to lay out the most promising innovations"Qiming Ventures and Dehong Capital are partners we trust," said MrZhai Zhenjun, co-founder and president of Qiming MedicalIn the course of many years of cooperation, the two investors have provided a large number of valuable advice to Qiming Medical at the level of operation management, merger and acquisition integration and capital operation, and formed a long-term partnership of mutual trust and win-win cooperationWe are therefore very pleased to continue to work with them on this investment We will take Jishi Capital as a new starting point for cooperation, and work together to continuously lay out the global innovative medical device industry Mr Liu Haifeng, Chairman of Dehong Capital, said, "Qiming Medical was founded by the best management team in the industry and is a leader in the innovation medical device industry." We are pleased to see that after years of rapid development, Qiming Medical has proven its industry-leading strategic vision and has gradually realized its industry footprint based on solid research and development strength and marketing capabilities Through our investment in Qiming Medical, we also see long-term opportunities in China's innovative medical device sector With this investment, we hope to discover more outstanding innovative medical device companies Ms Liang yu, Managing Partner of Qiming Ventures, said: "We have witnessed the whole process of Qiming Medical from scratch to gradual growth and development, and we are convinced of the company's team's judgment on the direction of technology and industry trends This time, I am very pleased to be able to work together again to set up an investment platform to promote the development of innovative medical device technology in the global and china, and to nurture more industry head enterprises "This gathering of medical industry and investment giants is expected to fully integrate the power of industry and capital, integrate talent and technology resources within the industry, and build an open medical innovation technology aircraft carrier to meet the huge medical needs of China and the global market in the future." About Hangzhou Qiming Medical Devices Co., Ltd Qiming Medical was established in 2009, located in Hangzhou National High-tech Industrial Development Zone (Riverside), committed to the development and industrialization of minimally invasive treatment of heart valve disease Qiming Medical focuses on research and development and has 2 world-leading products: dry membrane pre-installed intervention valves and interventional self-sptentating pulmonary valves The company has conducted a number of innovative research and trials, including the first clinical research in the field of catheter valves, the implantation and testing of Chinese heart valve devices in Europe, and the establishment of the Heart Valve Research Institute in China Qiming currently has the first NMPA-approved transdermal interventional artificial heart valve system About Dehong Capital Dehong Capital is an international private equity firm focused on the Asian market Dehong Capital's core team has led KKR and Morgan Stanley's private equity investment stakes in Asia and has generated long-term, excellent return on investment across multiple cycles Dehong Capital has received strong support from leading international and domestic long-term institutional investors, including sovereign wealth funds, pension funds, endowmentfunds, parent funds and family funds In the past 27 years, Dehong Capital has invested in a series of pioneering projects in China's PE sector, supporting many leading Chinese enterprises, such as Ping An, Mengniu Dairy, Qingdao Haier, CICC, Far East Hongxin, Qiming Medical, China Cord Blood Bank, Modern Pastoral, Hengan International, Nanfu Battery, Baili International, Cofco Meat, United Environment and so on With its international investment experience and local izeder resource network, Dehong Capital has accumulated deep industry expertise and solid post-investment management capabilities Dehong Capital upholds the concept of value investment, aiming to establish long-term win-win partnership with invested enterprises, to create value for the long-term development of invested enterprises About Qiming Ventures Was established in 2006 with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and the San Francisco Bay Area At present, Qiming Ventures manages nine US dollar funds and five RMB funds with total assets under management of more than US$5.3 billion Since its inception, it has focused on investing in early and long-term excellence in industries such as TMT and Healthcare Up to now, Qiming Ventures has invested in more than 350 high-growth innovative enterprises, including more than 110 in the United States NYSE, NASDAQ, Hong Kong Stock Exchange, Taiwan Counter BuyIng Center, SSE and Shenzhen Stock Exchange and other exchanges listed, and mergers and other exit, more than 30 enterprises have become the industry recognized as unicorns and super unicorn enterprises Many of the most influential companies in their fields have grown into investment companies, including Xiaomi Group (01810 HK, American Group Reviews (03690 HK), Beep (NASDAQ: BILI), Stone Technology (688169 SH), Gan Li Pharmaceuticals (603087 SH), Tiger Pharmaceuticals (300347 SZ), Reding Pharmaceuticals (NASDAQ: ZLAB), Qiming Medical (02500 HK), Considine Bio (06185 HK), Schr?dinger (NASDAQ: SDGR), Sanyou Medical (688085 SH), Ed Creatures (300685 SZ), Berry Gene (000710 SZ), Shenzhou Cell (688520 SH), micro-medical group, must-have, etc